Therapeutic

Vertex’s “Fantasy project” with Moderna pushes CF limits

Vertex’s “Fantasy project” with Moderna pushes CF limits

Vertex Pharmaceuticals and Moderna announced in 2022 their strategic research collaboration aimed at the “discovery and development of lipid nanoparticles (LNPs) and mRNAs”. This partnership is part of Vertex’s larger project to find suitable Cystic Fibrosis (CF)...

2030 AIDS elimination goals for new WHO alliance

2030 AIDS elimination goals for new WHO alliance

The recent UNAIDS report revealed that only 52% of children with HIV are receiving life-saving treatment. However, 76% of adults with HIV are receiving antiretrovirals. The gap in coverage is “an outrage”, according to UNAIDS Executive Director Winnie Bynanyima. She...

Continuing the Covid-19 fight with monoclonal antibodies

Continuing the Covid-19 fight with monoclonal antibodies

As the Covid-19 pandemic continues across the globe, novel variants mutate and rise against current treatments. The protection afforded by vaccination wanes after a few months, and therapies that previously worked are ineffective against more recent instalments. Thus,...

China’s antiviral pill: from HIV to Covid-19

China’s antiviral pill: from HIV to Covid-19

In July 2022 China’s drug regulator gave conditional approval for Azvduine, an HIV drug developed by Genuine Biotech, to be used in the treatment of Covid-19. Specific data from clinical trials were not released but the company announced that in a Phase III clinical...

Together against Alzheimer’s: where do we stand?

Together against Alzheimer’s: where do we stand?

Some of the most common indicators of Alzheimer’s disease include build-ups of beta-amyloid plaques, tau proteins, and neuroinflammation. These are the targets for a vaccine against Alzheimer’s progression. One of the simpler methods to vaccine development is...

High hopes for collaborative HIV vaccine development

High hopes for collaborative HIV vaccine development

In March 2022 Dr Anthony Fauci, director of NIAID, reflected that developing an effective HIV vaccine is a “daunting scientific challenge”. He identifies the obstacles: genetic variability, ability to establish lifelong infection, and human inability to clear HIV...

Diabetes developments, Provention and Diamyd

Diabetes developments, Provention and Diamyd

Historic diabetes treatment focuses on treating the condition with insulin. However, recent immunotherapies move towards the potential to delay or prevent type 1 diabetes (T1D). Provention Bio, Inc. is a biopharmaceutical company focused on the interception and...